Trial intelligence / Profile preview

CITRIC study of cetuximab plus irinotecan rechallenge versus investigator's choice in ctDNA-selected metastatic colorectal cancer

2024-518728-59-00Phase 2Completed

Sponsor: SOLTI
Start: Oct 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Countries: 1

Overview

Phase 2, randomised, open-label trial of cetuximab and irinotecan in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by SOLTI. Primary endpoint: Objective response rate. Started Oct 2024; status: completed.

Drugs

cetuximabirinotecan

Conditions

metastatic colorectal adenocarcinoma (mCRC)

Beyond the preview

Go deeper on 2024-518728-59-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-518728-59-00.